Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB4211
    • CB5138 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay
News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Jan 07, 2015 5:00pm EST

CohBar, Inc. Completes US$11.25M IPO to Discover and Develop Novel Mitochondrial-derived Therapeutics

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
©2023 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use